10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2016 | |||
CONSOLIDATED STATEMENTS OF CASH FLOWS | |||
Period Ending Dec 31, 2016 10-K (Filed: Feb 9, 2017) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | |
| Cash flows from operating activities: | |||
| Net income | $ 895,522 | 636,056 | 338,126 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 104,745 | 74,909 | 52,686 |
| Non-cash compensation expense | 559,878 | 459,049 | 321,750 |
| Other non-cash charges and expenses, net | 45,139 | 52,562 | 77,571 |
| Deferred Taxes | (360,078) | (121,623) | (53,276) |
| Changes in assets and liabilites | |||
| Increase in Sanofi, Bayer, and trade accounts receivable | (143,827) | (491,421) | (34,927) |
| Increase in Inventories | (149,776) | (111,825) | (56,947) |
| Decrease (increase) in prepaid expenses and other assets | 23,543 | (79,476) | (45,327) |
| Increase (decrease) in deferred revenue | 244,270 | 608,892 | (8,403) |
| Increase in accounts payable, accrued expenses and other liabilities | 253,980 | 303,657 | 161,182 |
| Total adjustments | 577,874 | 694,724 | 414,309 |
| Net cash provided by operating activities | 1,473,396 | 1,330,780 | 752,435 |
| Cash flows from investing activities: | |||
| Purchases of marketable securities | (809,419) | (557,105) | (564,188) |
| Sales or maturities of marketable securities | 274,456 | 327,437 | 476,417 |
| Capital expenditures | (511,941) | (677,933) | (333,006) |
| Net cash used in by investing activities | (1,046,904) | (907,601) | (420,777) |
| Cash flows from financing activities: | |||
| (Payments) proceeds in connection with capital and facility lease obligations | (27,689) | 26,020 | (1,095) |
| Repayments of convertible senior notes | (12,894) | (166,467) | (220,639) |
| Payments in connection with reduction of outstanding warrants | (643,365) | (573,487) | (294,552) |
| Proceeds from issuance of Common Stock | 126,739 | 206,358 | 126,045 |
| Payments in connection with Common Stock tendered for employee tax obligations | (143,182) | (160,537) | (267,584) |
| Excess tax benefit from stock-based compensation | 0 | 405,317 | 439,278 |
| Net cash (used in) provided by financing activities | (700,391) | (262,796) | (218,547) |
| Net (decrease) increase in cash and cash equivalents | (273,899) | 160,383 | 113,111 |
| Cash and cash equivalents at beginning of period | 809,102 | 648,719 | |
| Cash and cash equivalents at end of period | 535,203 | 809,102 | 648,719 |
| Cash paid for interest (net of amounts capitalized) | 5,454 | 10,582 | 20,348 |
| Cash paid for income taxes | 481,360 | 276,092 | 59,847 |
| Class of Warrant or Right | |||
| Warrant | |||
| Payments in connection with reduction of outstanding warrants | (399,500) | (294,600) | |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2016 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |